New models, cell lines and assays have been added at the firm's new oncology centre in San Diego
Crown Bioscience, a global drug discovery and development services company, has expanded its oncology services with new models, cell lines and assays at its Centre of Excellence for Oncology in San Diego, CA, US.
The firm enlarged this Centre last month, adding multiple holding rooms and dedicated procedure and formulation space.
These services introduce technology for the evaluation of immuno-oncology programmes, while also adding new technologies for traditional cancer agents.
CrownBio has added highly characterised syngeneic in vivo services, while expanding its flow cytometry laboratories to support both syngeneic and humanised PDX studies.
Mike Prosser, CrownBio’s General Manager of European and North American operations, said the firm now has the capability to offer a significantly extended range of services, from in vitro screening to later stage translational studies, including avatar clinical trials (HuTrials) with Humanised NSG xenografts to evaluate the efficacy of anticancer immunotherapy before entering the clinic.
CrownBio has also developed new PDX-derived cell lines to expand its PrimePanel collection with primary cells from Caucasian, pretreated and metastatic tumour samples to help evaluate traditional oncology agents.
Additionally, the firm has developed expanded 3D-tumour growth assays (3D-TGA) for most indications to provide translational in vitro models aligned to the tumour micro-environment.
'These new services will allow us to provide our clients, leading global biopharmaceutical companies, with local access to a range of platforms, including advanced models that more accurately reflect tumour microenvironments, thereby offering better screening tools for evaluating innovative oncology drug candidates,' added Jean-Pierre Wery, CEO of CrownBio.